Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 8:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 453 matching trials from the live ClinicalTrials.gov search.
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
Video recording, Notes Instruction
Behavioral
Lead sponsor
Trustees of Dartmouth College
Other
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
7
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Boston, Massachusetts + 4 more
Completed Phase 2 Interventional Results available

Mexiletine in Sporadic Amyotrophic Lateral Sclerosis

NCT02781454
Conditions
Sporadic Amyotrophic Lateral Sclerosis
Interventions
Mexiletine, Placebo
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
10
States / cities
Phoenix, Arizona • Orange, California • Augusta, Georgia + 7 more
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
NurOwn® (MSC-NTF cells), Placebo, Bone Marrow aspiration
Biological · Other
Lead sponsor
Brainstorm-Cell Therapeutics
Industry
Eligibility
18 Years to 60 Years
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
6
States / cities
Irvine, California • Los Angeles, California • San Francisco, California + 3 more
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Expiratory Muscle Strength Training (EMST-150)
Device
Lead sponsor
Purdue University
Other
Eligibility
40 Years to 70 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
West Lafayette, Indiana
Conditions
ALS (Amyotrophic Lateral Sclerosis)
Interventions
Digoxin
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
Davie, Florida • Chicago, Illinois • Boston, Massachusetts
Conditions
Amyotrophic Lateral Sclerosis
Interventions
STR04
Biological
Lead sponsor
New England Cell Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Austin, Texas
Conditions
Tetraplegia/Tetraparesis, Amyotrophic Lateral Sclerosis (ALS), Quadriplegia, Spinal Cord Injury (SCI), Spinal Cord Injury Cervical
Interventions
Assistive Robotic Arm
Device
Lead sponsor
Neuralink Corp
Industry
Eligibility
Not listed
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
1
States / cities
Phoenix, Arizona
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Levosimendan
Drug
Lead sponsor
Orion Corporation, Orion Pharma
Industry
Eligibility
18 Years to 120 Years
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
31
States / cities
Phoenix, Arizona • La Jolla, California • Orange, California + 23 more
Conditions
Amyotrophic Lateral Sclerosis
Interventions
prosetin, placebo
Drug
Lead sponsor
ProJenX
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts • San Antonio, Texas
Conditions
Amyotrophic Lateral Sclerosis
Interventions
GDC-0134, Placebo, Rabeprazole, Midazolam, Caffeine
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
8
States / cities
San Francisco, California • Jacksonville, Florida • Miami, Florida + 5 more
Completed Phase 2 Interventional Results available

Gilenya in Amyotrophic Lateral Sclerosis (ALS)

NCT01786174
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Gilenya, Placebo
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
4
States / cities
Orange, California • Augusta, Georgia • Boston, Massachusetts + 1 more
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Exercise
Procedure
Lead sponsor
University of Saskatchewan
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2004
U.S. locations
1
States / cities
Cleveland, Ohio
Completed No phase listed Observational Accepts healthy volunteers

Amyotrophic Lateral Sclerosis (ALS) Tissue Donation Program

NCT00716131
Conditions
Amyotrophic Lateral Sclerosis, Neurodegenerative Disease, Motor Neuron Disease
Interventions
Not listed
Lead sponsor
Drexel University College of Medicine
Other
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Amyotrophic Lateral Sclerosis, Stroke
Interventions
Use of BCI
Device
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
16 Years to 100 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Amyotrophic Lateral Sclerosis
Interventions
TCH346
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years to 75 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002
U.S. locations
1
States / cities
New York, New York
Not listed No phase listed Observational Accepts healthy volunteers

A Longitudinal Analysis of Biomarkers in Patients With ALS

NCT05309408
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Venipuncture, Lumbar Puncture
Diagnostic Test
Lead sponsor
Holy Cross Hospital, Florida
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
Rasagiline, Placebo
Drug
Lead sponsor
Richard Barohn, MD
Other
Eligibility
21 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
10
States / cities
Phoenix, Arizona • Irvine, California • San Francisco, California + 7 more
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Gold Nanocrystals
Drug
Lead sponsor
Clene Nanomedicine
Industry
Eligibility
35 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Ibudilast
Drug
Lead sponsor
MediciNova
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
Boston, Massachusetts • Patchogue, New York
Conditions
Amyotrophic Lateral Sclerosis
Interventions
MyoRegulator®
Device
Lead sponsor
PathMaker Neurosystems Inc.
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Charlestown, Massachusetts
Conditions
Amyotrophic Lateral Sclerosis
Interventions
nL-CHCHD-001
Drug
Lead sponsor
n-Lorem Foundation
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Terminated Phase 3 Interventional Results available

A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031)

NCT05442775
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Reldesemtiv
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
21
States / cities
Phoenix, Arizona • Orange, California • San Francisco, California + 17 more
Conditions
Amyotrophic Lateral Sclerosis
Interventions
NurOwn (MSC-NTF cells)
Biological
Lead sponsor
Brainstorm-Cell Therapeutics
Industry
Eligibility
18 Years to 63 Years
U.S. locations
5
States / cities
Irvine, California • San Francisco, California • Boston, Massachusetts + 2 more
Conditions
Neuromuscular Diseases (NMD), Amyotrophic Lateral Sclerosis, Myasthenia Gravis, Lambert-eaton Myasthenic Syndrome, Primary Lateral Sclerosis, Spinal Muscular Atrophy, Charcot Marie Tooth Disease (CMT), Fascioscapulohumeral Muscular Dystrophy, Inclusion Body Myositis, Mitochondrial Myopathy, Nemaline Myopathy, Centronuclear Myopathy, Postpolio Syndrome, Pompe Disease (Late-onset), Chronic Inflammatory Demyelinating Polyneuropathy, Hereditary Spastic Paraplegia, Postural Orthostatic Tachycardia Syndrome (POTS), Progressive Muscular Atrophy
Interventions
Whole-body Electrical Muscle Stimulation Exercise
Device
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Columbia, Missouri